Idiosyncratic reactions: New methods of identifying high-risk patients

Epilepsia

Volumn 41, Issue SUPPL. 8, 2000, Pages

  Glauser, Tracy A ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Epilepsy; Felbamate; Glutathione peroxidase; Idiosyncratic drug reactions; Lamotrigine

Indexed keywords

ANTICONVULSIVE AGENT; BIOLOGICAL MARKER; DRUG METABOLITE; FELBAMATE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; LAMOTRIGINE; SCAVENGER; SELENIUM; SUPEROXIDE DISMUTASE; VALPROIC ACID;

ADULT; APLASTIC ANEMIA; CALCULATION; CHILD; CLINICAL FEATURE; DRUG EFFECT; DRUG INDUCED DISEASE; ENZYME ACTIVITY; EPILEPSY; FEMALE; GENETIC MARKER; HIGH RISK POPULATION; HUMAN; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING TEST; TREATMENT OUTCOME;

EID: 0033764534     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.2000.tb02943.x     Document Type: Review

References (79)

1. Idiosyncratic drug reactions: A mechanistic evaluation of risk factors
2. The role of active metabolites in drug toxicity
3. Adverse drug effect - Reactive metabolites and idiosyncratic drug reactions: Part I
4. The role of leukocyte-generated reactive metabolites in the pathogenesis of idiosyncratic drug reactions
5. New concepts in immunology relevant to idiosyncratic drug reactions: The 'danger hypothesis' and innate immune system
6. Hypersensitivity syndrome to antiepileptic drugs: A review including new anticonvulsants
7. Idiosyncratic drug reactions: Possible role of reactive metabolites generated by leukocytes
8. Valproic acid hepatic fatalities. III. U.S. experience since 1986
9. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs
10. Lamotrigine-induced severe cutaneous adverse reactions
11. Hepatic considerations in the use of antiepileptic drugs
12. Hepatic toxicity of antiepileptic drugs: A review
13. Carbamazepine side effects in children and adults
14. Standard approach to antiepileptic drug treatment in the United States
15. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: A record linkage study
16. Idiosyncratic reactions to the antiepileptic drugs
17. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: A case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions
18. A comparative review of the adverse effects of anti-convulsants in children with epilepsy
19. Managing pediatric epilepsy syndromes with new antiepileptic drugs
20. Mechanisms of drug reactions: The metabolic track
21. Myeloperoxidase as a generator of drug free radicals
22. Covalent binding of carbamazepine oxidative metabolites to neutrophils
23. Current trends in drug-induced autoimmunity
24. Free radical scavenging enzyme activity profiles in risk assessment of idiosyncratic drug reactions
25. Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy
26. Valproic acid hepatic fatalities: A retrospective review
27. Valproic acid hepatic fatalities. II. US experience since 1984
28. Valproate toxicity: Risk-screening strategies
29. Felbamate
30. Felbamate: 1997 update
31. Lamotrigine
32. Overview of lamotrigine and the new antiepileptic drugs: The challenge
33. In vitro assessment of pharmacogenetic susceptibility to toxic drug metabolites in humans
34. Altered antioxidant enzyme activities in children with a serious adverse experience related to valproic acid therapy
35. Abnormalities in free radical scavenging enzyme activity in patients with felbamate-associated aplastic anemia
36. Non-dose-related side effects of valproate
37. Valproate-induced hepatic injury: Analyses of 23 fatal cases
38. Routine laboratory monitoring for serious adverse effects of antiepileptic medications: The controversy
39. Idiosyncratic drug-induced haematological abnormalities. Incidence, pathogenesis, management and avoidance
40. Felbamate
41. Potentially reactive cyclic carbamate metabolite of the antiepileptic drug felbamate produced by human liver tissue in vitro
42. Identification of modified atropaldehyde mercapturic acids in rat and human urine after felbamate administration
43. Quantification in patient urine samples of felbamate and three metabolites: Acid carbamate and two mercapturic acids
44. In vitro analysis of idiosyncratic drug reactions
45. Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions
46. Genetic analysis of microsomal epoxide hydrolase in patients with carbamazepine hypersensitivity
47. Free radical-mediated diseases in pediatrics
48. Definitions, properties, and reactions of radicals
49. Mechanisms of radical production
50. Regulatory antioxidant enzymes
51. Neutrophil oxidants: Production and reactions
52. Mechanism of action of biological antioxidants
53. Small molecule antioxidant defenses in human extracellular fluids
54. Biological functions of selenium
55. Glutathione metabolism and its selective modification
56. Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione
57. Metabolic activation and drug toxicity
58. Glutathione peroxidase deficiency and childhood seizures
59. Post-traumatic epilepsy: Cellular mechanisms and implications for treatment
60. Free radical disorders of preterm infants
61. Erythrocyte antioxidant enzyme activities in children with myelomeningocele
62. Comparison of erythrocyte antioxidant enzyme activities and embryologic level of neural tube defects
63. Surgery for congenital heart disease: Plasma antioxidant depletion after cardiopulmonary bypass in operations for congenital heart disease
64. Reactive oxygen species and the neurodegenerative disorders
65. Plasma trace element, plasma glutathione peroxidase, and superoxide dismutase levels in epileptic children receiving antiepileptic drug therapy
66. Biological variability of superoxide dismutase, glutathione peroxidase, and catalase in blood
67. Changes in oxygen-metabolizing enzymes and lipid peroxidation in human erythrocytes as a function of age of donor
68. Age-correlated modifications of copper-zinc superoxide dismutase and glutathione-related enzyme activities in human erythrocytes
69. Concentration of zinc-copper superoxide dismutase activity in red blood cells in normals and children with cancer
70. Developmental patterns of antioxidant defense mechanisms in human erythrocytes
71. Blood activity of Cu/Zn superoxide dismutase, glutathione peroxidase and catalase in Alzheimer's disease: A case-control study
72. Valeurs usuelles du selenium et de la glutathione peroxidase dans une population Belge
73. Ethnic variation in red cell glutathione peroxidase activity
74. Racial differences in free radical scavenging enzyme activity in children
75. Alternative approaches to the prediction of antiepileptic, idiosyncratic, or drug-drug interactions
76. Glutathione peroxidase, V. The kinetic mechanism
77. Progress in felbamate research: Toxic metabolite test and HLA typing